Journal article
Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer
- Abstract:
-
Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic delivery and currently undergoing clinical evaluation for advanced cancer therapy. For differentiated carcinomas, systemic delivery would likely expose virus particles to the basolateral surface of cancer cells rather than the apical surface encountered during natural infection. Here, we compare the ability of EnAd and adenovirus type-5 (Ad5) to infect polarised colorectal carcinoma cells from the apical or basolat...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Virology Journal website
- Volume:
- 505
- Pages:
- 162-171
- Publication date:
- 2017-03-03
- Acceptance date:
- 2017-02-14
- DOI:
- EISSN:
-
1096-0341
- ISSN:
-
0042-6822
- Source identifiers:
-
685428
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:685428
- UUID:
-
uuid:416e9ef6-a8f3-4c65-b21b-96fd145f78e9
- Local pid:
- pubs:685428
- Deposit date:
- 2017-07-25
Terms of use
- Copyright holder:
- Chia et al
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 Published by Elsevier Inc.
If you are the owner of this record, you can report an update to it here: Report update to this record